Reimbursing infliximab for Crohn's disease is cost-effective in Chinese patients.

One of the collaboration projects of Normin Health has been published in Advances in Therapy. This project leveraged the real-world data from a tertiary care hospital to evaluate the impact of reimbursing infliximab on clinical outcomes and medical costs associated with moderate to severe Crohn's disease in real-world setting. The real-world data were used to develop a cost-effectiveness model to further evaluate the cost-effectiveness of this reimbursement policy with literature evidence, which mainly established the impact of disease remission on the surgery risk, complications, survival, and quality of life. The results suggested that reimbursing infliximab was cost-effective by gaining health benefits with acceptable reimbursement costs in Chinese patients with Crohn's disease. To simulate the natural history of Crohn's disease, Normin Health has developed a comprehensive model illustrated below. For more details, please click here.